A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes
Phase of Trial: Phase IV
Latest Information Update: 01 Jan 2018
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms IMPROVE
- 01 Jan 2018 Status changed from recruiting to completed, according to results published in the Diabetes, Obesity and Metabolism.
- 07 Jun 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-000157-37)
- 07 Jun 2014 According to the European Clinical Trials Database record, status changed from not yet recruiting to recruiting.